Australian, U.K. Firms To Join In Creating Early Alzheimer’s Test
This article was originally published in PharmAsia News
Executive Summary
Australia's Alzhyme Pty and Senexis of the United Kingdom have signed an agreement to work on discovering a new way to diagnose Alzheimer's disease. Such a test would be a first for a disease that usually begins years before clinical symptoms are observed. The collaboration is aimed at developing a diagnostic test kit reliable and inexpensive enough to allow routine detection of biomarkers in the blood. The two companies see a $1 billion global market for such a test as the number of cases doubles over the next two decades. (Click here for more
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.